[IL-2 bronchoscopic istillation and immune cell activation: preliminary results of the BRIIL-2 study for treatment of pulmonary metastasis from renal cancer and melanoma]

M Filippetti; A Torsello; P Cordiali Fei; V Bordignon; E Trento; R Tonachella; G Piperno; G Prignano

[IL-2 bronchoscopic istillation and immune cell activation: preliminary results of the BRIIL-2 study for treatment of pulmonary metastasis from renal cancer and melanoma]

Clin Ter. 2009;160(2):139-43.

[Article in Italian]

Authors

M Filippetti¹, A Torsello, P Cordiali Fei, V Bordignon, E Trento, R Tonachella, G Piperno, G Prignano

Affiliation

¹ Endoscopia Toracica, Istituto Regina Elena, Via Elio Chianesi 53, Rome, Italy. [email protected]

PMID: 19452104

Abstract

BRIIL-2 is a clinical study for evaluation of efficacy and toxicity of third line treatment of pulmonary metastasis from renal cancer and melanoma with flexible bronchoscopic istillation of IL-2. Moreover, we evaluate local (BALT) and peripheral lymphocytic activation during this IL-2 administration. Up today we enrolled two patients with pulmonary metastasis from renal cancer already treated with two lines of molecular therapy, chemotherapy or systemic immunotherapy. Regarding to immunologic stimulation, lymphocytic fraction decreased from 21 to 2% in the first and from 10.5 to 6% in the second patient, indicating lymphocytic enrollment for activation, while TCD4/CD8 ratio is stable. In both patients we also observed a significant increase of HLA-DR in T lymphocytes (CD3) either in BAL or in peripheral blood. No significant major toxicities were observed after broncho-istillation, even if the dose was progressively increased. Thus IL-2 broncho-istillation could represent a valid administration modality to obtain an effective immunologic stimulation either local or systemic.

Publication types

Case Reports
Clinical Trial
English Abstract

MeSH terms

Bone Neoplasms / secondary
Bone Neoplasms / therapy
Bronchoalveolar Lavage Fluid / cytology
Bronchoscopy*
Carcinoma, Renal Cell / blood
Carcinoma, Renal Cell / immunology
Carcinoma, Renal Cell / secondary*
Carcinoma, Renal Cell / surgery
Carcinoma, Renal Cell / therapy
Combined Modality Therapy
Female
Fiber Optic Technology
HLA-DR Antigens / biosynthesis
HLA-DR Antigens / genetics
Humans
Instillation, Drug
Interleukin-2 / administration & dosage
Interleukin-2 / therapeutic use*
Kidney Neoplasms / blood
Kidney Neoplasms / immunology
Kidney Neoplasms / pathology*
Kidney Neoplasms / surgery
Lung Neoplasms / blood
Lung Neoplasms / immunology
Lung Neoplasms / secondary*
Lung Neoplasms / therapy
Lymphocyte Activation / drug effects
Lymphocyte Count
Lymphocyte Subsets / drug effects
Lymphocyte Subsets / immunology
Lymphocyte Subsets / metabolism
Male
Melanoma / secondary
Melanoma / therapy
Middle Aged
Nephrectomy
T-Lymphocytes / drug effects*
T-Lymphocytes / immunology
T-Lymphocytes / metabolism

Substances

HLA-DR Antigens
Interleukin-2